# Haiyi Jiang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/haiyi-jiang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,389 |
| Field | Lung Cancer Research Studies |
| h-index | 34 |
| i10-index | 43 |
| Last Known Institution | AstraZeneca (Netherlands) |
| OpenAlex ID | https://openalex.org/A5061878462 |
| ORCID iD | https://orcid.org/0009-0002-8677-6821 |
| Works | 189 |

## Researcher papers

- [Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma](https://scholariq.org/papers/gefitinib-or-carboplatin-paclitaxel-in-pulmonary-adenocarcinoma/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)](https://scholariq.org/papers/biomarker-analyses-and-final-overall-survival-results-from-a-phase-iii/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Interstitial Lung Disease in Japanese Patients with Lung Cancer](https://scholariq.org/papers/interstitial-lung-disease-in-japanese-patients-with-lung-cancer/)
- [Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-egfr-mutation/)
- [Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-v-15-32-of-gefitinib-versus-docetaxel-in-previously-treated/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)

## Researcher university

- [AstraZeneca (Netherlands)](https://scholariq.org/institutions/astrazeneca-netherlands/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.